Orexigen’s Big Plans On Hold As FDA Hashes Out Post-Marketing Requirements
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Weight loss drug Contrave delayed by three months while sponsor and agency discuss how to handle data transparency for ongoing cardiovascular outcomes trial.